Ocular Therapeutix Inc (OCUL) - Product Pipeline Analysis, 2018 Update

Ocular Therapeutix Inc (OCUL) - Product Pipeline Analysis, 2018 Update


  • Products Id :- GDME225416PD
  • |
  • Pages: 33
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Ocular Therapeutix Inc (Ocular), formerly I-Therapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company's products include DEXTENZA, sustained release travoprost and posterior segment injections. Its hydrogel technology uses polyethylene glycol to create ophthalmic sustained drug delivery systems. Ocular's hydrogel provides containment, localization and protection from inflammatory response, and a material for sustained delivery of drugs to the eye. The company also provides ReSure Sealant, a ocular sealant proven in clinical trial to be safe in sealing clear corneal incisions following cataract surgery. Its products are used for the treatment of glaucoma and ocular hypertension, post-operative inflammation, allergic conjunctivitis, dry eye and retinal diseases. Ocular is headquartered in Bedford, Massachusetts, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Ocular Therapeutix Inc

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Ocular Therapeutix Inc Company Overview 4

Ocular Therapeutix Inc Company Snapshot 4

Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview 4

Ocular Therapeutix Inc-Pipeline Analysis Overview 7

Ocular Therapeutix Inc-Key Facts 7

Ocular Therapeutix Inc-Major Products and Services 8

Ocular Therapeutix Inc Pipeline Products by Development Stage 9

Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status 11

Ocular Therapeutix Inc Pipeline Products Overview 12

DEXTENZA 12

DEXTENZA Product Overview 12

OTX-IVT 13

OTX-IVT Product Overview 13

OTX-MP 14

OTX-MP Product Overview 14

OTX-TIC 15

OTX-TIC Product Overview 15

OTX-TIC Clinical Trial 16

OTX-TKI 17

OTX-TKI Product Overview 17

OTX-TP 18

OTX-TP Product Overview 18

OTX-TP Clinical Trial 19

Ocular Therapeutix Inc-Key Competitors 20

Ocular Therapeutix Inc-Key Employees 21

Ocular Therapeutix Inc-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Ocular Therapeutix Inc, Recent Developments 23

Jul 19, 2018: Ocular Therapeutix Announces FDA Acceptance of NDA Resubmission for DEXTENZA 23

Jun 29, 2018: Ocular Therapeutix Announces NDA Resubmission of DEXTENZA 23

May 03, 2018: Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC (travoprost intracameral implant) for the Treatment of Glaucoma and Ocular Hypertension 23

Apr 09, 2018: Ocular Therapeutix to Present Data at the American Society of Cataract and Refractive Surgery Symposium 24

Mar 08, 2018: Ocular Therapeutix Reports Fourth Quarter and Year End 2017 Financial Results and Business Update 24

Jan 08, 2018: Ocular Therapeutix Announces Kevin Hanley as Senior Vice President, Technical Operations and Naymisha Patel as Vice President of Quality 26

Dec 22, 2017: Ocular Therapeutix Provides Legal Update 26

Nov 07, 2017: Ocular Therapeutix Reports Third Quarter 2017 Financial Results and Provides Corporate Update 27

Sep 25, 2017: Ocular Therapeutix Appoints Donald Notman as Chief Financial Officer 28

Sep 08, 2017: Ocular Therapeutix Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer 28

Appendix 30

Methodology 30

About GlobalData 33

Contact Us 33

Disclaimer 33

List of Figures

Ocular Therapeutix Inc Pipeline Products by Equipment Type 5

Ocular Therapeutix Inc Pipeline Products by Development Stage 9

Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status 11

List of Tables

Ocular Therapeutix Inc Pipeline Products and Ongoing Clinical Trials Overview 4

Ocular Therapeutix Inc Pipeline Products by Equipment Type 5

Ocular Therapeutix Inc Pipeline Products by Indication 6

Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status 6

Ocular Therapeutix Inc, Key Facts 7

Ocular Therapeutix Inc, Major Products and Services 8

Ocular Therapeutix Inc Number of Pipeline Products by Development Stage 9

Ocular Therapeutix Inc Pipeline Products Summary by Development Stage 10

Ocular Therapeutix Inc Ongoing Clinical Trials by Trial Status 11

Ocular Therapeutix Inc Ongoing Clinical Trials Summary 11

DEXTENZA-Product Status 12

DEXTENZA-Product Description 12

OTX-IVT-Product Status 13

OTX-IVT-Product Description 13

OTX-MP-Product Status 14

OTX-MP-Product Description 14

OTX-TIC-Product Status 15

OTX-TIC-Product Description 15

OTX-TIC-To Evaluate the Safety, Efficacy, Durability, and Tolerability of OTX-TIC in Patients with Primary Open-angle Glaucoma or Ocular Hypertension 16

OTX-TKI-Product Status 17

OTX-TKI-Product Description 17

OTX-TP-Product Status 18

OTX-TP-Product Description 18

OTX-TP-Non-significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug 19

Ocular Therapeutix Inc, Key Employees 21

Ocular Therapeutix Inc, Other Locations 22

Glossary 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Acucela Inc

Neurocrine Biosciences Inc

Otonomy Inc

Pfizer Inc

Sorrento Therapeutics Inc

Ocular Therapeutix Inc, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies

select a license

Single User License
USD 750 INR 53910
Site License
USD 1500 INR 107820
Corporate User License
USD 2250 INR 161730

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com